Susac综合征:系统回顾和生存分析。

IF 11.3 2区 医学 Q1 ALLERGY
Gian Marco Pace, Luca Canali, Domenico Villari, Giuseppe Spriano, Giuseppe Mercante, Isabelle Mosnier, Daniele Bernardeschi, Giovanni Colombo, Matteo Di Bari
{"title":"Susac综合征:系统回顾和生存分析。","authors":"Gian Marco Pace, Luca Canali, Domenico Villari, Giuseppe Spriano, Giuseppe Mercante, Isabelle Mosnier, Daniele Bernardeschi, Giovanni Colombo, Matteo Di Bari","doi":"10.1007/s12016-025-09087-6","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this study is to analyze data from all cases of Susac syndrome that have been published in the literature. This study was conducted in conformity with the PRISMA statement. A systematic review and survival analysis was performed for overall survival (OS) and progression-free survival (PFS). A total of 435 patients (males: 32.6%, n = 142), derived from 176 studies, were included in the analysis. The median age at diagnosis was 35 years (n = 433/435; range 7-69). Neurological symptoms were the most frequent (87.4%, n = 380/435). Among audio-vestibular symptoms (84.3%, n = 365/433), hearing loss was the most common manifestation (87.9%, n = 327/372). Branch retinal artery occlusions (BRAOs) were observed in 91.6% of patients (n = 261/285), while ophthalmological symptoms were reported in 78.9% (n = 288/365). The complete triad at onset was present in only 20.1% (n = 61/304) of cases. Complete recovery without sequelae was achieved in 59.5% (n = 44/74) of patients which reported neurological involvement, 39.7% (n = 27/68) of those with ophthalmological symptoms, and 17.7% (n = 11/62) of those with audio-vestibular symptoms. Partial recovery was observed in 36.5% (n = 27/74), 50.0% (n = 34/68), and 38.7% (n = 24/62) of patients, respectively. In a subgroup of 123 patients with available follow-up data (median duration: 12 months), 82.1% (n = 101) remained stable with controlled disease, 12.2% (n = 15) experienced a relapse, and 5.7% (n = 7) died. OS at 1 and 3 years was 94% (95% CI 88-97%). PFS was 89% at 1 year (95% CI: 80-94%) and 83% at 3 years (95% CI: 69-91%). Susac syndrome presents a significant clinical challenge. While presentations and outcomes are very heterogeneous, mortality is uncommon. The potential for relapse and long-term sequelae highlights the need for greater awareness and deeper understanding of the disease.</p>","PeriodicalId":10423,"journal":{"name":"Clinical Reviews in Allergy & Immunology","volume":"68 1","pages":"73"},"PeriodicalIF":11.3000,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Susac Syndrome: A Systematic Review and Survival Analysis.\",\"authors\":\"Gian Marco Pace, Luca Canali, Domenico Villari, Giuseppe Spriano, Giuseppe Mercante, Isabelle Mosnier, Daniele Bernardeschi, Giovanni Colombo, Matteo Di Bari\",\"doi\":\"10.1007/s12016-025-09087-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The aim of this study is to analyze data from all cases of Susac syndrome that have been published in the literature. This study was conducted in conformity with the PRISMA statement. A systematic review and survival analysis was performed for overall survival (OS) and progression-free survival (PFS). A total of 435 patients (males: 32.6%, n = 142), derived from 176 studies, were included in the analysis. The median age at diagnosis was 35 years (n = 433/435; range 7-69). Neurological symptoms were the most frequent (87.4%, n = 380/435). Among audio-vestibular symptoms (84.3%, n = 365/433), hearing loss was the most common manifestation (87.9%, n = 327/372). Branch retinal artery occlusions (BRAOs) were observed in 91.6% of patients (n = 261/285), while ophthalmological symptoms were reported in 78.9% (n = 288/365). The complete triad at onset was present in only 20.1% (n = 61/304) of cases. Complete recovery without sequelae was achieved in 59.5% (n = 44/74) of patients which reported neurological involvement, 39.7% (n = 27/68) of those with ophthalmological symptoms, and 17.7% (n = 11/62) of those with audio-vestibular symptoms. Partial recovery was observed in 36.5% (n = 27/74), 50.0% (n = 34/68), and 38.7% (n = 24/62) of patients, respectively. In a subgroup of 123 patients with available follow-up data (median duration: 12 months), 82.1% (n = 101) remained stable with controlled disease, 12.2% (n = 15) experienced a relapse, and 5.7% (n = 7) died. OS at 1 and 3 years was 94% (95% CI 88-97%). PFS was 89% at 1 year (95% CI: 80-94%) and 83% at 3 years (95% CI: 69-91%). Susac syndrome presents a significant clinical challenge. While presentations and outcomes are very heterogeneous, mortality is uncommon. The potential for relapse and long-term sequelae highlights the need for greater awareness and deeper understanding of the disease.</p>\",\"PeriodicalId\":10423,\"journal\":{\"name\":\"Clinical Reviews in Allergy & Immunology\",\"volume\":\"68 1\",\"pages\":\"73\"},\"PeriodicalIF\":11.3000,\"publicationDate\":\"2025-07-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Reviews in Allergy & Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12016-025-09087-6\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Reviews in Allergy & Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12016-025-09087-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

摘要

本研究的目的是分析文献中已发表的所有Susac综合征病例的数据。这项研究是按照PRISMA声明进行的。对总生存期(OS)和无进展生存期(PFS)进行了系统评价和生存分析。来自176项研究的435例患者(男性:32.6%,n = 142)被纳入分析。诊断时的中位年龄为35岁(n = 433/435;射程7 - 69)。神经系统症状最为常见(87.4%,n = 380/435)。在听庭症状中(84.3%,n = 365/433),听力损失是最常见的表现(87.9%,n = 327/372)。91.6%的患者(n = 261/285)出现视网膜分支动脉闭塞(bros), 78.9%的患者(n = 288/365)出现眼科症状。只有20.1% (n = 61/304)的病例在发病时出现完全的三联征。59.5% (n = 44/74)有神经系统受累的患者、39.7% (n = 27/68)有眼科症状的患者和17.7% (n = 11/62)有听庭症状的患者完全康复,无后遗症。36.5% (n = 27/74)、50.0% (n = 34/68)和38.7% (n = 24/62)的患者部分恢复。在123例有随访资料的患者亚组中(中位持续时间:12个月),82.1% (n = 101)病情稳定,病情得到控制,12.2% (n = 15)复发,5.7% (n = 7)死亡。1年和3年的OS为94% (95% CI 88-97%)。1年PFS为89% (95% CI: 80-94%), 3年PFS为83% (95% CI: 69-91%)。Susac综合征是一项重大的临床挑战。虽然表现和结果非常不同,但死亡率并不常见。复发和长期后遗症的可能性突出了提高认识和深入了解这种疾病的必要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Susac Syndrome: A Systematic Review and Survival Analysis.

The aim of this study is to analyze data from all cases of Susac syndrome that have been published in the literature. This study was conducted in conformity with the PRISMA statement. A systematic review and survival analysis was performed for overall survival (OS) and progression-free survival (PFS). A total of 435 patients (males: 32.6%, n = 142), derived from 176 studies, were included in the analysis. The median age at diagnosis was 35 years (n = 433/435; range 7-69). Neurological symptoms were the most frequent (87.4%, n = 380/435). Among audio-vestibular symptoms (84.3%, n = 365/433), hearing loss was the most common manifestation (87.9%, n = 327/372). Branch retinal artery occlusions (BRAOs) were observed in 91.6% of patients (n = 261/285), while ophthalmological symptoms were reported in 78.9% (n = 288/365). The complete triad at onset was present in only 20.1% (n = 61/304) of cases. Complete recovery without sequelae was achieved in 59.5% (n = 44/74) of patients which reported neurological involvement, 39.7% (n = 27/68) of those with ophthalmological symptoms, and 17.7% (n = 11/62) of those with audio-vestibular symptoms. Partial recovery was observed in 36.5% (n = 27/74), 50.0% (n = 34/68), and 38.7% (n = 24/62) of patients, respectively. In a subgroup of 123 patients with available follow-up data (median duration: 12 months), 82.1% (n = 101) remained stable with controlled disease, 12.2% (n = 15) experienced a relapse, and 5.7% (n = 7) died. OS at 1 and 3 years was 94% (95% CI 88-97%). PFS was 89% at 1 year (95% CI: 80-94%) and 83% at 3 years (95% CI: 69-91%). Susac syndrome presents a significant clinical challenge. While presentations and outcomes are very heterogeneous, mortality is uncommon. The potential for relapse and long-term sequelae highlights the need for greater awareness and deeper understanding of the disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
22.30
自引率
1.10%
发文量
58
审稿时长
6-12 weeks
期刊介绍: Clinical Reviews in Allergy & Immunology is a scholarly journal that focuses on the advancement of clinical management in allergic and immunologic diseases. The journal publishes both scholarly reviews and experimental papers that address the current state of managing these diseases, placing new data into perspective. Each issue of the journal is dedicated to a specific theme of critical importance to allergists and immunologists, aiming to provide a comprehensive understanding of the subject matter for a wide readership. The journal is particularly helpful in explaining how novel data impacts clinical management, along with advancements such as standardized protocols for allergy skin testing and challenge procedures, as well as improved understanding of cell biology. Ultimately, the journal aims to contribute to the improvement of care and management for patients with immune-mediated diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信